Israel Charo
Corporate Officer/Principal bij The University of California, San Francisco
Actieve functies van Israel Charo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| The University of California, San Francisco | Corporate Officer/Principal | 01-01-1991 | - |
Loopbaan van Israel Charo
Eerdere bekende functies van Israel Charo
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CHEMOCENTRYX, INC. | Hoofd Techniek/Wetenschap/O&O | 01-09-2014 | - |
| Corporate Officer/Principal | 01-09-2014 | - | |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Private Equity Investor | 15-12-2010 | 15-12-2010 |
| Corporate Officer/Principal | 15-12-2010 | - |
Opleiding van Israel Charo
| State University of New York at Downstate Medical Center | Doctorate Degree |
| Stony Brook University | Undergraduate Degree |
| University of California, Berkeley | Graduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 7 |
Operationeel
| Corporate Officer/Principal | 3 |
| Private Equity Investor | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sectoraal
| Consumer Services | 5 |
| Finance | 2 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Bay City Capital LLC
Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
ChemoCentryx, Inc.
 ChemoCentryx, Inc. Pharmaceuticals: MajorHealth Technology ChemoCentryx, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in San Carlos, CA. | Health Technology |
- Beurs
- Insiders
- Israel Charo
- Ervaring
